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INTRODUCTION
In recent years, there have been rapid developments in
new techniques for the optimal management of
patients with malignant hematological disease. Despite
the increased contribution of immunological, cyto-
genetical and molecular investigations, morphological
examination remains the ﬁrst step for rapid and accu-
rate diagnosis and optimal follow-up of patients with
malignant blood diseases. This step requires a high
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SUMMARY
The CellaVision
TM DM96 is an automated image analysis system
dedicated to locating and preclassifying the various types of white
blood cells in peripheral blood smears. The system also partially
characterizes of the red blood cell morphology and is able to perform
platelet counts. We routinely analyzed the blood samples from 440
patients with quantitative and/or qualitative abnormalities detected by
the XE-2100 Sysmex
TM.O n l y2 . 6 %o fc e l l sa r en o ti d e n t i ﬁ e db y
DM96
TM. After classiﬁcation of the unidentiﬁed cells very good
correlation coefﬁcients are observed between DM96
TM and manual
microscopy for most hematological parameters and accuracy is judged
excellent up to 98%. For most common parameters, false positive and
false negative ratios are also very good. Whatever the pathology and
the number of blasts on smear, all patients were positive for blast
d e t e c t i o no nD M 9 6
TM. The system is a useful tool for assisting in the
diagnosis and classiﬁcation of most acute or chronic leukemia.
Automatic cell location and preclassiﬁcation, along with unique cell
views on the computer screen, could reduce the time spent performing
differentials and make real-time collaboration between colleagues a
natural part of the classiﬁcation process. The workstation also provides
an ergonomically correct and relaxed working environment. We
suggest its use in routine analysis; the system could be very helpful for
the accurate morphological diagnosis of samples from patients with
malignant hematological disease.
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rate assessment of cellular morphology. Despite the sig-
niﬁcant improvements during the last years in
hematology analyzers, no signiﬁcant progress has been
made in terms of automatic examination of peripheral
blood cells. Irrespective of the analyzer, approximately
15% of the blood samples require manual microscopic
observation either because of biological rules or ana-
lyzer ﬂags. The relative number of samples to be
reviewed will probably not decrease in years to come.
Smear examinations are time consuming and require
well-trained medical technologists and biologists.
Microscopy automation should be available in
hematology laboratories. The decrease of cytology pro-
ﬁciency in the daily practice, the need for development
of new innovative techniques in hematology laborato-
ries in the face of limited human resources, and ﬁnally,
the increase and the complexity of pathologies attribut-
able to population aging create a need for automation
of the cytology platform in all laboratories. In this con-
text, we had the opportunity to evaluate the CellaVi-
sion
TM DM96 automated microscope (CellaVision AB,
Ideon Research Park, SE-223, 70 Lund, Sweden) in the
hematology laboratory at Caen University Hospital. The
academic hospital has 1750 active beds and the labora-
tory performs 500–600 Complete Blood Count with
Differential (CBC-DIFF) per day with XE-2100 Sys-
mex
TM analyzers (Sysmex Corporation 1-S-1, Wakino-
hama Kaygandori, Cho-Ku, Kobe 651-0073, Japan).
Adult and pediatric hematology account for 10% of the
demands, oncology represents 15% and surgical and
intensive cares about 20%. We evaluated CellaVision
TM
DM96 and discuss how such a device could be inte-
grated into the daily routine and the performance of
DM96
TM in the diagnosis and monitoring of patients
with malignant hematological diseases.
MATERIALS AND METHODS
The automated microscope DM 96
CellaVision
TM DM96 is an automated device for the
differential counting of white blood cells (WBCs) and
characterization of red blood cells (RBCs). It consists
of a slide feeder unit, a microscope with three objec-
tives (·10, ·50, and ·100), a camera and a computer
system containing the acquisition and classiﬁcation
software CellaVision
TM blood differential software
(Figure 1). A slide autoloader facilitates the automatic
analysis of up to 96 smears with continuous loading
access. The number of WBC to be analyzed is user
deﬁnable from 100 up to 400. To perform a differen-
tial count, a thin ﬁlm of blood is wedged on a glass
slide (a blood smear) from a peripheral blood sample
and stained according to the May-Grunwald Giemsa
protocol. The analyzer performs the acquisition and
preclassiﬁcation of cells and the operator subsequently
veriﬁes and modiﬁes, if necessary, the suggested clas-
siﬁcation of each cell (Figure 2). The operator can also
introduce additional observations and comments
when needed. For this reason, persons specially
trained in the use of this instrument and skilled in the
recognition of cells can operate the DM96
TM. The sys-
tem makes the following WBC classiﬁcations: band
neutrophils, segmented neutrophils, eosinophils, ba-
sophils, monocytes, lymphocytes, promyelocytes, my-
elocytes, metamyelocytes, blast cells, variant form
lymphocytes and plasma cells. The system also pre-
classiﬁes non-WBC into the following classiﬁcations:
erythroblasts, giant thrombocytes, thrombocytes
aggregation, smudge cells and artifacts. ‘Unidentiﬁed’
is a class of cells and objects that the system cannot
identify. The system has four ﬂag levels for the fol-
lowing RBC morphological characteristics: polychrom-
asia, hypochromasia, anisocytosis, microcytosis,
macrocytosis, and poikilocytosis. Besides the WBCs
mentioned above, the operator or ‘user’ can reclassify
Figure 1. DM96
TM: an automated device for the
differential counting of white blood cells (WBCs).
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eosinophils, immature basophils, promonocytes,
prolymphocytes, large granular lymphocytes, hairy
cells, Sezary cells, others, megacaryocyte, not classed,
and 15 user-deﬁned classes. The operator can also add
the following characteristics for RBCs: schizocytosis,
helmet cells, sickle cells, spherocytosis, elliptocytosis,
ovalocytosis, teardrop cells, stomatocytosis, acanto-
cytosis, and echinocytosis, Howell–Jolly bodies, Pap-
penheimer bodies, basophilic stippling, parasites, and
10 other deﬁnable characteristics.
Smears and stains
Slides analyzed by the DM96
TM were prepared with
SP-100 SYSMEX
TM from venous blood sample col-
lected in EDTA-type anticoagulant and previously
analyzed with XE-2100 SYSMEX
TM. Staining program
and reagents were as follows: May Grunwald (MG)
and Giemsa (Biolyon, France), MG pure time:
2.5 min, MG dilute time: 3 min, Giemsa time: 7 min,
rinse 0 min and drying time 5 min.
Patients
Four hundred and forty nonselected patients pro-
cessed with the XE-2100 were analyzed by medical
technologists experienced using both conventional
microscopy method and DM96
TM. All these samples
were abnormal according to routine laboratory criteria
and hence, justiﬁed a manual smear review (quantita-
tive abnormality, qualitative ﬂag from XE-2100
TM,
malignant hematological disease). Under the micro-
scope, 100 leucocytes were observed for establishing
the control differential and a mean of 110 leucocytes
were required for DM96
TM.
To analyze the performance of automated micro-
scopy with DM96
TM and measure its impact on labo-
ratory organization and workﬂow, we studied its
ability to correctly identify blood cells and accuracy
compared with manual method and/or XE-2100
TM.
Finally, we analyzed the sensitivity for detection of
pathological cells in case of hematological disease.
Efﬁciency of cell recognition
We analyzed the accuracy in classifying normal and
abnormal cells for routine parameters by DM96
TM
(neutrophils, eosinophils, basophils, lymphocytes,
monocytes, immature granulocytes, and erythroblasts)
out of 62904 cells [including Nucleated Red Blood
Cells (NRBCs) and smudge cells] issued from the 440
patients analyzed. Efﬁciency of recognition has been
calculated for each cell category. Unidentiﬁed cells
from DM96
TM have been studied as well and their
inﬂuence on the above-mentioned result calculated.
Comparison with manual method
We did not test normal blood samples in this study as
this had already been performed and the results
showed DM96
TM to be reliable and accurate (Ceelie,
Dinkelaar & van Gelder, 2007). The results of 356
patients with no hematological disease but laboratory
Figure 2. DM96
TM performs the
acquisition and preclassiﬁcation
of cells and the operator subse-
quently veriﬁes and modiﬁes, if
necessary, the suggested classiﬁ-
cation of each cell.
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after medical technologist reclassiﬁcation with the
manual differentials performed by the same user and
to XE-2100
TM. Correlation between DM96
TM and both
manual count and XE-2100
TM result was established
for neutrophils, eosinophils, basophils, lymphocytes,
monocytes, erythroblasts, and immature granulocytes
(including metamyelocytes, myelocytes, and promyel-
ocytes). In case of disagreement, a clinician reanalyzed
both the slide and the validation issued from
DM96
TM.
Malignant hematological diseases
We focused then on 84 patients with malignant
hematological disorders from various types. The classi-
ﬁcation of these 84 patients was made according to
the WHO criteria (Harris et al.,1999) and is described
in table 1. Blast recognition and quantiﬁcation by
DM96
TM was studied in 34 patients, acute lympho-
blastic leukemia (ALL), acute myeloid leukemia
(AML) or chronic myeloproliferative disorders/myelo-
dysplastic syndromes (CMPD/MDS). Three patients
were excluded for the analysis in the absence of blasts
cells in the peripheral blood. All these three patients
had myelodysplasic syndromes (MDS). For all other
patients, B-cell chronic lymphocytic leukemia (CLL),
other B-cell chronic lymphoproliferative disorders
(B-CLPD), we focused on capacity of DM96
TM to efﬁ-
ciently recognize mature cells and provide images per-
mitting an easy and reliable morphological
classiﬁcation.
Statistical analysis
Statistical analysis was performed using Microsoft
 
Excel software. For correlation analysis, we used two-
tailed paired t-tests to evaluate differences between
the percentage of blast cells detected by DM96
TM and
manual microscope in patients with blast cells in the
peripheral blood. Clinical sensitivity and speciﬁcity of
the CellaVision DM96
TM were deﬁned as its ability to
obtain positive and negative results concordant with
medical technologist before and after classiﬁcation of
unidentiﬁed cells by DM96
TM.
RESULTS
Accuracy of cell recognition
Only 2.6% of cells are not identiﬁed (especially
NRBCs and immature granulocytes) leading the global
efﬁciency of DM96
TM to 95% of direct correct identiﬁ-
cation. In total, when reclassifying unidentiﬁed cells
by medical technologist, accuracy is judged excellent
up to 98%. For most common parameters, false posi-
tive and false negative ratio are very good (Table 2).
Comparison with manual method
Correlation for DM96
TM results with the manual
method and/or XE-2100
TM is excellent for neutroph-
ils, lymphocytes, eosinophils, and acceptable for
immature granulocytes, erythroblasts, and for basoph-
ils. The correlation observed for monocytes was not as
good as expected; both results (DM96
TM and optical
manual count) were usually lower than the automatic
count but this was not clinically relevant.
Patients with malignant hematological diseases
Patients with blasts on smear
Whatever the pathology (AML, ALL, and CMPD/
MDS) and the number of blasts on smear, all 34
patients were positive for blast detection on DM96
TM.
Additionally, it appears very easy to distinguish mye-
loid blasts from lymphoid blasts. Despite DM96
TM
underestimates the number of blasts cells (especially
in ALL where a huge number of them is misclassi-
ﬁed as lymphocytes), after manual validation, the
Table 1. Distribution of the hematological diseases in
84 patients
Acute myeloid leukemia (AML) 17
Acute lymphoid leukemia (ALL) 10
Myeloproliferative/myelodysplastic syndromes
(MPD/MDS)
10
B-cell chronic lymphocytic leukemia (CLL) 25
Other B-cell chronic lymphoproliferative disorders 22
Mantle cell lymphoma (MCL) 5
Follicular lymphoma (FL) 1
Diffuse large B-cell lymphoma (DLBCL) 7
Hodgkin lymphoma (HL) 1
Splenic lymphoma with villous lymphocytes (SLVL) 3
Hairy cell leukemia (HCL) 1
Persistent polyclonal B lymphocytosis (PPBL) 3
Large granular lymphocytes leukemia (LGL) 1
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(Figure 3). In patients with chronic myeloproliferative
disorders or myelodysplastic syndromes, both the
quantitative and qualitative analysis of immature
granulocytes was comparable with the one observed
for routine patients. Basophiles were clearly identiﬁed
even when they show abnormal aspects. Blast count
for these patients appeared to be reliable.
B-cell chronic lymphoproliferative disorders
DM96
TM classiﬁes CLL cells without problem but
often provides a wide count of ‘smudge cells’ arising
from the smear method. The recommended procedure
in this case is still to use the lymphocyte count from
the analyzer as the most reliable result. Concerning
other lymphoid pathologies summarized in Table 1, as
the DM96
TM only gets capacities for 4 cells groups
(lymphocytes, variant lymphocytes, plasma cells,
blasts) it is not able to classify correctly these abnor-
mal samples. Such classiﬁcation remains under the
responsibility of medical technologist. Observation of
lymphoid cells on DM96
TM screen allowed an easy
and accurate identiﬁcation of abnormal cells such as
large granular lymphocytes (LGL), binucleated lym-
phoid cells and hairy cells, which are not expected to
be classiﬁed directly by the DM96
TM supports to
clearly identify the exact disease under consideration
[splenic lymphoma with villous lymphocytes (SLVL),
Table 2. Comparaison between DM96
TM before and after classiﬁcation of unidentiﬁed cells and manual differential
counts
Cell per cell analysis with DM 96: pool of 62 904 cells
DM96
TM\user Neutrophils Eosinophils Basophils Lymphocytes Monocytes IG NRBC total
Before unidentiﬁed cells classiﬁcation
Unidentiﬁed 796 36 9 56 214 353 157 1621
Accuracy (%) 95.6 96 80 99 92 58 56 95
After unidentiﬁed cells classiﬁcation (%)
Accuracy 98 98 83 99 98 86 82 98
False negative 2.3 1.5 17.3 0.5 2.4 14.4 17.9
False positive 0.0 12.3 39.3 2.2 4.9 46.2 6.3
IG, Immature Granulocytes; NRBC, nucleated red blood cell.
Figure 3. Blasts log scale.
Figure 4. The overview of tumoral lymphoid cells
facilitates the efﬁcient distinction between typical
chronic lymphocytic leukemia and other B-cell
chronic lymphoproliferative disorders.
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ure 4].
DISCUSSION
The DM96
TM has already proven to be reliable for
normal patient samples. In this study, we became
aware of the capabilities and limitations of the auto-
mated microscope DM96
TM for analyzing patient sam-
ples with quantitative and qualitative abnormalities
detected by XE-2100
TM. From a biological point of
view, we as others (Swolin et al., 2003; Kratz et al.,
2005; Roumier et al., 2005; Contis & Williams, 2006,
2006) demonstrated that the results obtained from
DM96
TM correlated well to those obtained by manual
counting of all patient samples, suggesting that
DM96
TM may be useful for the analysis of the great
majority of parameters tested. About monocytes,
heterogeneous distribution on slides is a well-known
problem arising directly from the smear method and
consequently, both the choice of the observation area
(which can be different for DM96
TM and manual
microscopy) and the number of cells analyzed contrib-
ute to the difference in monocyte counts.
Modern characterization of acute malignant hema-
tological disease is a multidisciplinary process. Ini-
tially, it requires the integration of clinical,
morphological and cytochemical information. A cor-
rect and rapid hematological evaluation is necessary
to follow-up with the appropriate laboratory tests,
speciﬁcally immunophenotyping, metaphase cytoge-
netics and molecular studies. However, the interpreta-
tion of morphological and cytochemical stains remains
central to the diagnosis and classiﬁcation of AML. The
identiﬁcation of multilineage dysplasia is entirely
dependent on light microscopic assessment of the leu-
kemia cells. Despite the advances in diagnostic tech-
nologies, the maintenance and improvement of
morphological skills still remain essential requirements
in the diagnosis of AML. In case of AML, DM96
TM is
able to detect blast cells and to identify myeloid blast
cells and maturing cells. In addition, it facilitates the
evaluation and quantiﬁcation of dysplasia on a high
number of myeloid cells preselected by DM96
TM,
which are then classiﬁed and eventually properly
reclassiﬁed by the biologist. In cases of B-ALL and
more generally in cases of myeloperoxydase (MPO)
negative blast cells, immunophenotyping is always
still required for the initial diagnosis. DM96 is also
able to detect blast cells but is unable to classify blast
cells as lymphoblasts. In this context, it makes sense
to rely upon conventional microscopy. If the sample
quality is poor, it will be also necessary to survey the
entire smear in manual mode. For post-treatment
monitoring of patients with malignant hematological
disease, DM96
TM represents a good tool for the detec-
tion of abnormal cells but is not appropriate for quan-
tifying blast cells in the peripheral blood of patients
with B-ALL. In cases of B-CLPD and when operated
by an experienced cytologist, DM96
TM is helpful for
identifying the disease and especially the lymphoid
abnormalities. As an example, we rapidly identiﬁed
binucleated lymphocytes characteristic of polyclonal
lymphocytosis with binucleated lymphocytes (Mossafa
et al. 1999), hairy cells in patients with HCL and atyp-
ical lymphocytes in patients with B-CLL. An overview
of all lymphoid cells is of great interest in lymphocyte
analysis.
Finally, DM96 proved to be fully comparable with
the manual method in a test using control patient
blood smears and in daily practice applicable to >90%
of the leucocytes review.
The validation and screening of abnormal smears
is one of the core competencies of the technical staff,
which is under the supervision of a biologist. For
such a routine process, a signiﬁcant timesaving could
be realized by implementing such a reliable auto-
matic system. Therefore, these observations should
provide food for thought when considering modali-
ties for improving the efﬁciency of a hematology
laboratory.
The routine introduction of DM96
TM will probably
have a great impact on the logistics and organization
of both specialized and general hematology laborato-
ries. Depending on the validation requirements and
guidelines in each country, all the smears performed
by SP-100
TM can be passed onto the DM96
TM in a
continuous mode. If, after the unidentiﬁed cells have
been identiﬁed, classiﬁed, conﬁrmed and validated,
there are no blasts present, the validation could be
carried out by the DM96
TM, except when particular
difﬁculties are encountered. For the technical staff,
the installation of DM96
TM would have many conse-
quences: the reduction of technical staff time at the
microscope while simultaneously increasing the efﬁ-
ciency of the workﬂow, the elimination of medical
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improved ergonomics of the workstation (elbows,
eyes, and back), reduction of the ﬁling of the blades
and ﬁnally, optimization of time and quality. The
introduction of DM96
TM could also optimize the time
of the biological staff and improve the proﬁciency of
morphological expertise. In addition, the easy and
clear presentation of all patient samples on a com-
puter screen will help ensure the quality of follow-up
care in cancer patients. The images can be transmitted
to other experts for consultation and conﬁrmation
and will facilitate validation of clinical protocols. We
also can hope for shorter response times, a reduction
in errors, an improvement in continued and advanced
education, possibly a redeployment of human
resources and a signiﬁcant cost reduction for a
hemogram.
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